erenity Neurotechnologies is developing CranioCalm as a first-stage product for chronic migraine pain relief. The system builds on ultrasound-powered neurostimulation research and focuses on optimizing an external wearable ultrasound emitter to directly modulate the occipital nerve without requiring an injectable implant. Designed for patient-administered use, the wearable could be positioned at the back of the head or neck and activated on demand for a treatment session. By reducing invasiveness, cost, and the need for repeated provider visits, CranioCalm aims to make neuromodulation-based pain relief more accessible for people with migraine and chronic migraine.